Published in N Engl J Med on May 24, 2012
The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved? Int J Radiat Oncol Biol Phys (2014) 2.28
Dose escalation, not "new biology," can account for the efficacy of stereotactic body radiation therapy with non-small cell lung cancer. Int J Radiat Oncol Biol Phys (2013) 1.94
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol (2013) 1.90
Charged particle therapy--optimization, challenges and future directions. Nat Rev Clin Oncol (2013) 1.70
Trial Watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2014) 1.49
Trial Watch: Anticancer radioimmunotherapy. Oncoimmunology (2013) 1.31
Intratumoral immunization: a new paradigm for cancer therapy. Clin Cancer Res (2014) 1.24
Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys (2015) 1.21
Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions. Clin Cancer Res (2015) 1.15
New challenges in high-energy particle radiobiology. Br J Radiol (2014) 1.08
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology (2015) 1.06
Radiation survivors: understanding and exploiting the phenotype following fractionated radiation therapy. Mol Cancer Res (2012) 1.02
Molecular radiobiology: the state of the art. J Clin Oncol (2014) 0.96
Trial Watch: Radioimmunotherapy for oncological indications. Oncoimmunology (2014) 0.91
Unlocking the combination: potentiation of radiation-induced antitumor responses with immunotherapy. Radiat Res (2014) 0.90
Proton radiobiology. Cancers (Basel) (2015) 0.89
Novel immune checkpoint blocker approved for the treatment of advanced melanoma. Oncoimmunology (2014) 0.84
Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell-Mediated Killing. Int J Radiat Oncol Biol Phys (2016) 0.82
Genomic Approaches to Understanding Response and Resistance to Immunotherapy. Clin Cancer Res (2016) 0.81
Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology (2016) 0.81
Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions. J Gastrointest Oncol (2013) 0.81
Emerging Treatment Paradigms in Radiation Oncology. Clin Cancer Res (2015) 0.79
Melanoma vaccines: mixed past, promising future. Surg Clin North Am (2014) 0.78
Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer? Oncoimmunology (2015) 0.78
Predictors of clinical response to immunotherapy with or without radiotherapy. J Radiat Oncol (2015) 0.77
Non-targeted effects of photon and particle irradiation and the interaction with the immune system. Front Oncol (2012) 0.77
Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol (2017) 0.75
Phase I Trial: SABR and Ipilimumab-Response. Clin Cancer Res (2017) 0.75
Effects of radiation on metastasis and tumor cell migration. Cell Mol Life Sci (2016) 0.75
Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46
In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol (2010) 3.88
T cells use two directionally distinct pathways for cytokine secretion. Nat Immunol (2006) 3.01
Molecular biomarker analyses using circulating tumor cells. PLoS One (2010) 2.38
Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys (2004) 1.70
Detection and characterization of cellular immune responses using peptide-MHC microarrays. PLoS Biol (2003) 1.62
Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab. Clin Cancer Res (2012) 1.54
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol (2005) 1.35
Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer. Clin Cancer Res (2011) 1.31
Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood (2004) 1.24
A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol (2012) 1.24
Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res (2012) 1.24
Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Res (2010) 1.24
The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res (2004) 1.22
Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood (2007) 1.14
A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys (2004) 1.12
Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol (2005) 1.08
Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer (2007) 1.08
Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors. Neoplasia (2012) 1.04
Metalloporphyrin synergizes with ascorbic acid to inhibit cancer cell growth through fenton chemistry. Cancer Biother Radiopharm (2010) 1.01
Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action. Mol Cancer Ther (2006) 0.98
Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. Free Radic Biol Med (2005) 0.97
Role of cell cycle in epidermal growth factor receptor inhibitor-mediated radiosensitization. Cancer Res (2009) 0.96
Sporadic versus Radiation-Associated Angiosarcoma: A Comparative Clinicopathologic and Molecular Analysis of 48 Cases. Sarcoma (2013) 0.95
Clinical manifestations of noncoronary atherosclerotic vascular disease after moderate dose irradiation. Cancer (2006) 0.95
Six degrees of separation: the oxygen effect in the development of radiosensitizers. Transl Oncol (2011) 0.94
MIRD continuing education: Bystander and low dose-rate effects: are these relevant to radionuclide therapy? J Nucl Med (2007) 0.94
Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide. Int J Radiat Oncol Biol Phys (2004) 0.94
Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res (2010) 0.91
Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma. Int J Radiat Oncol Biol Phys (2006) 0.89
The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res (2002) 0.86
Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo. Mol Cancer Ther (2008) 0.85
Radiotherapy using a water bath in the treatment of Bowen's disease of the digit. Radiother Oncol (2008) 0.85
Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy. J Clin Invest (2013) 0.84
Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review. Transl Oncol (2012) 0.84
Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer. Int J Radiat Oncol Biol Phys (2008) 0.82
Darbepoietin alfa potentiates the efficacy of radiation therapy in mice with corrected or uncorrected anemia. Cancer Res (2005) 0.82
Targeting integrins and PI3K/Akt-mediated signal transduction pathways enhances radiation-induced anti-angiogenesis. Radiat Res (2007) 0.82
Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line. Clin Immunol (2013) 0.82
Topical hypochlorite ameliorates NF-κB-mediated skin diseases in mice. J Clin Invest (2013) 0.82
Comparative study of class 1 integron, ampicillin, chloramphenicol, streptomycin, sulfamethoxazole, tetracycline (ACSSuT) and fluoroquinolone resistance in various Salmonella serovars from humans and animals. Comp Immunol Microbiol Infect Dis (2012) 0.81
Radiation-induced cyclooxygenase 2 up-regulation is dependent on redox status in prostate cancer cells. Radiat Res (2003) 0.81
Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions. J Gastrointest Oncol (2013) 0.81
Radioprotection and cell cycle arrest of intestinal epithelial cells by darinaparsin, a tumor radiosensitizer. Int J Radiat Oncol Biol Phys (2013) 0.81
Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer. Clin Cancer Res (2012) 0.80
Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin). Semin Oncol (2003) 0.80
Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. Cancer Biother Radiopharm (2006) 0.80
Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma. J Nucl Med (2009) 0.80
Enhanced effectiveness of radiochemotherapy with tirapazamine by local application of electric pulses to tumors. Radiat Res (2004) 0.79
Mitigation of radiation-induced dermatitis by activation of aldehyde dehydrogenase 2 using topical alda-1 in mice. Radiat Res (2012) 0.79
Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys (2006) 0.79
Application of Scutellariae radix, Gardeniae fructus, and Probiotics to Prevent Salmonella enterica Serovar Choleraesuis Infection in Swine. Evid Based Complement Alternat Med (2013) 0.78
Sodium selenite radiosensitizes hormone-refractory prostate cancer xenograft tumors but not intestinal crypt cells in vivo. Int J Radiat Oncol Biol Phys (2010) 0.78
Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status. Cancer Lett (2010) 0.77
The scarlet letter of alkylation: a mini review of selective alkylating agents. Transl Oncol (2012) 0.77
131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma. Mol Imaging Biol (2009) 0.77
Effects of cerivastatin withdrawal on statin persistence. Ann Pharmacother (2008) 0.76
ALARA: in radiation oncology and diagnostic imaging alike. Oncology (Williston Park) (2014) 0.75
Phase I study of a modified regimen of ⁹⁰Yttrium-ibritumomab tiuxetan for relapsed or refractory follicular or transformed CD20+ non-Hodgkin lymphoma. Cancer Biother Radiopharm (2013) 0.75
Lanreotide promotes apoptosis and is not radioprotective in GH3 cells. Endocr Relat Cancer (2009) 0.75
Distribution of monoclonal antiferritin antibody in Kaposi's sarcoma, Hodgkin's disease, and hepatocellular carcinoma. Hum Pathol (2003) 0.75
Enhancement of the efficacy of an antagonist of an extracellular receptor by attachment to the surface of a biocompatible carrier. Pharm Res (2004) 0.75